Biobeat Technologies raised $50 million in a Series B announced December 30, 2025. Ally Bridge Group, OrbiMed Advisors and Elevage Medical co-led, joined by an unnamed strategic investor. The company is based in Petah Tikva, Israel, with U.S. operations in Boca Raton, Florida.
Biobeat's chest-worn patch estimates blood pressure from pulse wave transit time, the delay between a pressure wave passing two points on the body. It records for 24 hours without an inflatable cuff. FDA cleared the current BB-613-BPM under K241066 on January 14, 2025, under product code DXN, after a 271-day review. Earlier versions of the patch cleared under K190792, K212153 and K222010 under the oximeter product code DQA.
The money funds a U.S. field sales team. The goal is to make the patch the default for 24-hour ambulatory blood pressure monitoring, which today means an arm cuff inflating overnight. The company cites more than 100 million U.S. hypertensive patients. Cuffless blood pressure has a credibility problem after years of consumer wearables. A DXN clearance with a 24-hour ambulatory claim separates a medical device from a wellness gadget.